酢酸クロルマジノン(プロスタール錠25)による前立腺肥大症の治療

概要

論文の詳細を見る
To the patients with benign prostatic hypertrophy, 59 to 84 in age, one tablet of chlormadinone acetate 25 mg tablet (Prostal(R)) was orally administered twice a day. The treatment was performed for 16 weeks and the following results were obtained. 1. The clinical efficacy was observed in 14 cases out of 20 cases (70%). There was no case in whom the symptom was aggravated. 2. The improvement in subjective symptoms was observed in 13 cases out of 20 cases (65%). 3. The improvement in objective findings was observed in 14 cases out of 20 cases (70%). The improvement was also proved in residual urine volume, maximum flow rate, residual rate and UCG in 17 cases out of 20 cases (85%), 13 cases out of 19 cases (68%), 12 cases out of 19 cases (63%) and 13 cases out of 16 cases (81%), respectively, 4. General blood test, liver function test and kidney function test were all normal except for one case of gastric ulcer in which general blood test at the time of completion of the treatment was found to be altered more 'than 10% in comparison with the pretreatment value. Moreover, at the completion of the treatment, even a transient increase in the kidney function test was observed in another case. However, there has been observed no other obvious influence. From these results as mentioned above, chlormadinone acetate 25 mg tablet (Prostal(R)) was evaluated to be a useful therapeutic drug for benign prostatic hypertrophy.
泌尿器科紀要刊行会の論文